Search Follow us
Refine By

Stock Exchange

Market Cap (m)

Analyst

Type of Publication

volition

1 - 6 of 6
Sort by: popularity | newest
Page  of 1
VolitionRx

Executive interview – VolitionRx

Edison TV: | Pharmaceutical & healthcare | 20 Aug 2018

Volition is a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers. The tests are based on the technology platform of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

VolitionRx

VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer

Edison TV: | Pharmaceutical & healthcare | 26 Feb 2018

VolitionRx Limited, a multi-national life sciences company developing simple, easy to use blood-based cancer tests, today announced interim results from a 680-subject clinical trial in colorectal cancer. The study demonstrates high detection rates of Stage I cancer and pre-cancerous adenomas in colorectal cancer using Volition’s Nu.Q™ blood test.

VolitionRx

Executive interview - VolitionRx

Edison TV: | Pharmaceutical & healthcare | 20 Nov 2017

An interview covering third quarter results and a business update with Cameron Reynolds, CEO of Volition, a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers.

VolitionRx

Executive interview - Volition Rx

Edison TV: | Pharmaceutical & healthcare | 18 Jul 2017

Volition America, a wholly owned subsidiary of VolitionRx Limited, announces a major new colorectal cancer screening trial with 13,500 patients. In collaboration with the Great Lakes New England Clinical Validation Center and funded by the US National Cancer Institute’s (NCI) Early Detection Research Network (EDRN), this clinical study will seek to validate a panel of biomarkers that include Volition’s Nu.Q Colorectal Cancer Screening test in a large asymptomatic population to support US regulatory approval.

VolitionRx

News Announcement - VolitionRx

Edison TV: | Pharmaceutical & healthcare | 03 Jan 2017

Volition is a multi-national company developing simple, easy-to-use, blood-based cancer tests to accurately diagnose a range of cancers.

VolitionRx

EXTENDED Executive Interview with VolitionRX’s CEO Cameron Reynolds

Edison TV: | Pharmaceutical & healthcare | 08 Sep 2016

VolitionRx (NASDAQ: VNRX), a life sciences company focused on developing diagnostic tests for cancer, announced on September 6th, that it expects to receive CE Marking on its Nu.Q Triage Colorectal Cancer Screening Test (blood test) in late 2016 and aims to begin marketing the test commencing in early 2017. The test, developed at Volition’s laboratories in Belgium in conjunction with Hvidovre Hospital, University of Copenhagen, has demonstrated the potential to reduce colonoscopies by 25% while maintaining almost 97% detection of colorectal cancer. Volition plans initially to focus its launch of the test in the EU member states, which have an aggregate screening age population of approximately 148 million persons.